Recent Updates
Recently added Catalysts
PHVS Positive Sentiment

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Pharvaris has reported its financial results for Q2 2026 and provided a business update. The company anticipates topline data from the pivotal Phase 3 CHAPTER-3 study of deucrictibant XR for HAE prophylaxis in the third quarter of 2026. Additionally, the NDA for deucrictibant IR is currently under FDA review, with a PDUFA date set for April 23, 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • Topline data from pivotal Phase 3 study expected soon.
  • NDA for deucrictibant IR is under FDA review.
  • MAA validated by the EMA indicates progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
8.8%
average across 6 past catalysts
Lead asset
Deucrictibant
Phase 3 · Hereditary Angioedema (HAE)

Full Press Release Details

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027; MAA validated by the EMA in July 2026 Enrollment ongoing in CREAATE, a pivotal study of

Frequently Asked Questions

What are the key updates from Pharvaris?

Pharvaris reported Q2 2026 results and updates on deucrictibant studies.

When is the topline data from CHAPTER-3 expected?

Topline data from the CHAPTER-3 study is expected in Q3 2026.

What is the PDUFA date for deucrictibant IR?

The PDUFA date for deucrictibant IR is April 23, 2027.

What regulatory validation did Pharvaris receive?

The MAA for deucrictibant was validated by the EMA in July 2026.

ShareAdd on Google
Tags: PHVS Viatris Investor Conferences Healthcare deucrictibant HAE FDA review EMA validation
Last updated: Aug 12, 2026

Biotech snapshot

Lead asset
DeucrictibantPhase 3
Hereditary Angioedema (HAE) →

Catalyst track record

+50%
best trade around PHVS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for PHVS.

See every catalyst's timing & PoA →